HealthPartners Institute, Research and Evaluation Division, 8170 33rd Ave S, Mail stop 21112R, Minneapolis, MN, 55425, USA.
Hennepin Healthcare, 701 Park Ave, Minneapolis, MN, 55415, USA.
BMC Prim Care. 2024 Oct 11;25(1):361. doi: 10.1186/s12875-024-02609-9.
Medications for opioid use disorder (MOUD), including buprenorphine, are effective treatments for opioid use disorder (OUD) and reduce risk for overdose and death. Buprenorphine can be prescribed in outpatient primary care settings to treat OUD; however, prior research suggests adherence to buprenorphine in these settings can be low. The purpose of this study was to identify the rates of and factors associated with buprenorphine adherence among patients with OUD in the first six months after a new start of buprenorphine.
Data were extracted from the electronic health record (EHR) from a large integrated health system in the upper Midwest. Patients with OUD (N = 345; Mean age = 37.6 years, SD 13.2; 61.7% male; 78% White) with a new start of buprenorphine between March 2019 and July 2021 were included in the analysis. Buprenorphine adherence in the first six months was defined using medication orders; the proportion of days covered (PDC) with a standard cut-point of 80% was used to classify patients as adherent or non-adherent. Demographic (e.g., age, sex, race and ethnicity, geographic location), service (e.g., encounters, buprenorphine formulations and dosage) and clinical (e.g., diagnoses, urine toxicology screens) characteristics were examined as factors that could be related to adherence. Analyses included logistic regression with adherence group as a binary outcome.
Less than half of patients were classified as adherent to buprenorphine (44%). Adjusting for other factors, male sex (OR = 0.34, 95% CI = 0.20, 0.57, p < .001) and having an unexpected positive for opioids on urine toxicology (OR = 0.42, 95% CI = 0.21, 0.83, p < .014) were associated with lower likelihood of adherence to buprenorphine, whereas being a former smoker (compared to a current smoker; OR = 1.82, 95% CI = 1.02, 3.27, p = .014) was associated with greater likelihood of being adherent to buprenorphine.
These results suggest that buprenorphine adherence in primary care settings may be low, yet male sex and smoking status are associated with adherence rates. Future research is needed to identify the mechanisms through which these factors are associated with adherence.
阿片类药物使用障碍(MOUD)药物,包括丁丙诺啡,是阿片类药物使用障碍(OUD)的有效治疗方法,可降低过量用药和死亡的风险。丁丙诺啡可在门诊初级保健环境中开处方治疗 OUD;然而,先前的研究表明,在这些环境中,丁丙诺啡的依从性可能较低。本研究的目的是确定在开始使用丁丙诺啡后的头六个月内,OUD 患者的丁丙诺啡依从率及其相关因素。
数据从中西部一个大型综合医疗系统的电子健康记录(EHR)中提取。分析纳入了 2019 年 3 月至 2021 年 7 月期间开始使用丁丙诺啡的 345 名 OUD 患者(平均年龄 37.6 岁,标准差 13.2;61.7%为男性;78%为白人)。在头六个月中,丁丙诺啡的依从性通过药物医嘱定义;采用标准 80%覆盖天数(PDC)来对患者进行分类,分为依从或不依从。将人口统计学(如年龄、性别、种族和民族、地理位置)、服务(如就诊、丁丙诺啡制剂和剂量)和临床(如诊断、尿液毒理学检测)特征作为可能与依从性相关的因素进行检查。分析包括将依从性组作为二分类结果的逻辑回归。
不到一半的患者被归类为丁丙诺啡的依从者(44%)。在调整其他因素后,男性(比值比[OR] = 0.34,95%置信区间[CI] = 0.20,0.57,p < .001)和尿液毒理学检测意外呈阿片类阳性(OR = 0.42,95%CI = 0.21,0.83,p < .014)与丁丙诺啡的低依从性相关,而曾吸烟者(与当前吸烟者相比;OR = 1.82,95%CI = 1.02,3.27,p = .014)与丁丙诺啡的高依从性相关。
这些结果表明,初级保健环境中的丁丙诺啡依从性可能较低,但男性和吸烟状况与依从率相关。需要进一步研究以确定这些因素与依从性相关的机制。